DBV Technologies S.A.
(NASDAQ: DBVT)
|
11:03 AM EDT, 04/23/24 | |||
---|---|---|---|---|
Last: $0.69 | Change: +0.03 | %Change: +4.39% | Volume: 57,740 |
Open: | $ 0.69 | Volume: | 57,740 | |
---|---|---|---|---|
High: | $ 0.71 | Yield(%) | 0.00 | |
Low: | $ 0.69 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 127.00M | |
EPS ($) | -0.38 | Shares Out: | 192.42M |
% Price Change (last 4 weeks): | -15.79 |
---|---|
% Price Change (last 13 weeks): | -24.02 |
% Price Change (last 26 weeks): | -38.22 |
% Price Change (last 52 weeks): | -58.43 |
% Price Change (year to date): | -30.73 |
Return on Equity (%): | -43.47 |
---|---|
Return on Assets (%): | -33.87 |
Return on Invested Capital (%): | -67.67 |
Gross Profit Margin (%): | n/a |
---|---|
Net Profit Margin (%): | n/a |
Operating Profit Margin (%): | 0.00 |
50-day Moving Average: | $0.79 |
---|---|
200-day Moving Average: | $1.09 |
Avg. Daily Vol. (last 50 days): | 57,791 |
Avg. Daily Vol. (last 200 days): | 192,708 |
52-wk high: | $2.37 |
52-wk low: | $0.65 |
Bid: | $0.67 |
Ask: | $0.70 |
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.
|
DBV Technologies S.A.
177-181, avenue Pierre Brossolette Montrouge IF 92120 Phone: 33.1.55.42.78.78 Fax: 33.1.43.26.10.83 http://www.dbv-technologies.com |
Earnings (1year) ($): | -0.38 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 0.73 |
Cash Flow ($): | -0.40 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | n/a |
Price/Book (x): | 1.31 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 4.26 |
---|---|
Current Ratio (x): | 4.26 |
LT Debt/Equity (x): | 3.23 |
Total Debt/Equity (x): | 10.26 |